Utility of synthetic electrospun fiber matrix in general surgery: From head to toe.

To highlight the role of a novel synthetic electrospun fiber matrix in the treatment of high-risk wounds across a range of etiologies. This was a retrospective study of patients at a single institution who underwent complex wound care treatment with at least 1 application of the electrospun fiber matrix from January 2021 to December 2022. Information regarding patient demographics, wound size and etiologies, pertinent medical history, and treatment outcomes was collected. Twenty-one patients with 24 complex wounds who received synthetic electrospun fiber matrix treatment were identified. Nineteen patients (22 wounds) met the inclusion criteria for analysis. Patient mean age was 63.58 ± 15.20 (range 34–90) years. A wide range of wound etiologies was represented, including transmetatarsal amputation secondary to frostbite (n = 1), post-Mohs defect (n = 2), acute trauma (n = 3), surgical dehiscence (n = 3), infected implanted medical device (n = 2), chronic ulcers (n = 3), partial ray resection (n = 1), pilonidal cyst (n = 1), rattlesnake bite (n = 1), necrotizing soft-tissue infection (n = 1), and others (n = 2). A total of 17 of 19 (89.5%) patients were observed to meet their individual clinical goals after application of the wound matrix. Wound ages ranged from 1 to 429 days before initial synthetic electrospun fiber matrix application. The synthetic nature of the matrix limits the risk of inflammatory response and is well tolerated, which demonstrates initial proof of concept of synthetic electrospun fiber matrix treatment in a variety of complex wounds. The positive results observed across this mixed etiology surgical analysis should be replicated in future controlled, single-etiology studies to further confirm the utility of the electrospun fiber matrix in the surgical setting. [ABSTRACT FROM AUTHOR]